皮肤活检实践影响:丹麦全国皮肤癌与黑色素瘤活检研究
该研究分析丹麦2007至2022年4,481,207份活检标本,评估皮肤活检数量与费用。活检数量2007至2021年增长39.1%,总体恶性BMR为4.1:1,黑色素瘤NNB为31.8,临床怀疑恶性或黑色素瘤者BMR为1.5:1、NNB为2.8。
要点
- 活检数量2007至2021年增长39.1%。
- 临床怀疑恶性或黑色素瘤时,BMR为1.5:1,NNB为2.8。
核心结论
- 具备活检前过滤功能的医疗系统可实现全球最低的BMR之一,但多数因怀疑恶性而切除的良性皮肤病变发生在费用高昂的医院环境中。
- 在诊断准确性研究中纳入活检的临床原因对NNB至关重要。
研究设计与样本
- 研究纳入丹麦病理数据库2007年1月至2022年6月的4,481,207份活检标本,其中151,988份来自癌症通路并纳入BMR主要分析。
- 采用全国活检报销费率及多个病理科的组织病理学检查成本,进行蒙特卡洛模拟的简单成本与敏感性分析。
主要发现
- 活检数量从2007年至2021年增长39.1%。
- 总体恶性BMR为4.1:1,黑色素瘤NNB为31.8。
- 临床怀疑恶性或黑色素瘤的活检BMR为1.5:1,NNB为2.8。
临床怎么用
- 在活检决策前实施过滤功能可能降低BMR,但需关注良性病变切除的地点以控制成本。
- 诊断准确性研究应报告活检的临床原因以正确解读NNB。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to a multitude of factors, skin cancer incidence is increasing and challenges medical professionals in biopsy decision-making. While skin cancer may have a profound impact on the patient and be costly for society, there is little knowledge about the number and cost of benign skin lesions biopsied as collateral damage. OBJECTIVES: This study evaluates the number and costs of skin biopsies in Denmark over 15 years, focusing on benign and malignant skin lesions and melanomas across medical settings. It aims to determine the benign to malignant ratio (BMR) and number needed to biopsy (NNB) and estimate the direct cost of benign skin lesion biopsies in the Cancer Pathway from the perspective of a public healthcare system. METHODS: The study included 4,481,207 biopsy specimens from January 2007 to June 2022 from the Danish Pathology Data Bank, of which 151,988 from the Cancer Pathway were included in the primary analysis of BMR. The national reimbursement rates for biopsies were used, alongside histopathological examination costs extracted from several pathology departments, for a Monte-Carlo simulation of a simple cost and sensitivity analysis. RESULTS: The number of biopsies increased by 39.1% from 2007 to 2021. Overall BMR for malignancy was 4.1:1, and NNB for melanoma was 31.8, but biopsies performed on clinical suspicion of malignancy or melanoma had a BMR and NNB of 1.5:1 and 2.8, respectively. The cost of benign skin biopsies performed on suspicion of cancer or melanoma in 2021 was €6.6M, predominantly in hospitals. CONCLUSIONS: A healthcare system that employs filtering functions before biopsy of skin lesions can achieve some of the lowest BMR reported in the world, but with most benign skin lesion excisions due to suspicion of malignancy performed in the expensive hospital setting. Including clinical reason for biopsy in diagnostic accuracy studies using NNB is crucial.
引用
- Nervil GG, Vestergaard T, Klausen S, et al. Impact of skin biopsy practices: A comprehensive nationwide study on skin cancer and melanoma biopsies. J Eur Acad Dermatol Venereol. 2024. PMID: 39394835. doi:10.1111/jdv.20371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。